vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. vTv Therapeutics' type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. The Company has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
Company Growth (employees)
vTv Therapeutics Office Locations
vTv Therapeutics Data and Metrics
vTv Therapeutics Financial Metrics
Revenue (Q1, 2017) | 30 k |
EBIT (Q1, 2017) | (13.8 m) |
Market capitalization (15-Aug-2017) | 47.8 m |
Cash (31-Mar-2017) | 45.2 m |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Revenue | 519 k | 634 k |
Revenue growth, % | 22% | |
R&D expense | 27.2 m | 45 m |
General and administrative expense | 9.1 m | 9.9 m |
Operating expense total | 38.7 m | 55.7 m |
EBIT | (38.1 m) | (55 m) |
EBIT margin, % | (7349%) | (8678%) |
Interest expense | (68 k) | (398 k) |
Interest income | 87 k | |
Net Income | (55.4 m) |
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|
Revenue | 133 k | 376 k | 182 k | 38 k | 30 k |
R&D expense | 6.6 m | 11.1 m | 12.1 m | 10.6 m | 11 m |
General and administrative expense | 2.4 m | 2.6 m | 2.7 m | 2.4 m | 2.8 m |
Operating expense total | 9 m | 13.7 m | 14.7 m | 13 m | 13.8 m |
EBIT | (9.4 m) | (13.5 m) | (14.6 m) | (13.5 m) | (13.8 m) |
EBIT margin, % | (7098%) | (3601%) | (8043%) | (35600%) | (45847%) |
Interest expense | 21 k | 21 k | 21 k | (559 k) | |
Interest income | 4 k | 21 k | 21 k | 21 k | 27 k |
Pre tax profit | (9.8 m) |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Cash | 88 m | 51.5 m |
Inventories | 1.1 m | 612 k |
Current Assets | 89.2 m | 52.1 m |
PP&E | 624 k | 444 k |
Total Assets | 91.5 m | 54.5 m |
Accounts Payable | 6.6 m | 11.4 m |
Total Debt | 22.1 m | |
Current Liabilities | 7.7 m | 11.4 m |
Total Liabilities | 22.9 m | |
Additional Paid-in Capital | 117.7 m | 124.2 m |
Retained Earnings | (196 m) | (215.5 m) |
Debt to Assets Ratio | 0.4 x |
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|
Cash | 97 m | 75.5 m | 63.8 m | 51.1 m | 45.2 m |
Current Assets | 97.8 m | 77.1 m | 64.3 m | 52.1 m | 45.9 m |
PP&E | 669 k | 545 k | 561 k | 493 k | 426 k |
Total Assets | 100.2 m | 79.6 m | 66.8 m | 54.7 m | 48.3 m |
Accounts Payable | 5.2 m | 8 m | 9.5 m | 10.2 m | 11.1 m |
Current Liabilities | 6.1 m | 8.7 m | 9.8 m | 10.6 m | 11.1 m |
Additional Paid-in Capital | 117.1 m | 119.5 m | 122.1 m | 122.8 m | 125.1 m |
Retained Earnings | (211.6 m) | (182.9 m) | (202 m) | (234.4 m) | (248.9 m) |
| USD | FY, 2015 | FY, 2016 |
|---|---|---|
Depreciation and Amortization | 501 k | 265 k |
Accounts Receivable | (69 k) | 69 k |
Inventories | 5.5 m | |
Accounts Payable | 2.9 m | 4.8 m |
Cash From Operating Activities | (36.9 m) | (48.2 m) |
Purchases of PP&E | (104 k) | (87 k) |
Cash From Investing Activities | (79 k) | (83 k) |
Long-term Borrowings | (89 k) | |
Cash From Financing Activities | 123.6 m | 11.8 m |
Interest Paid | 75 k | 242 k |
| USD | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
|---|---|---|---|---|---|
Accounts Payable | 5.2 m | 8 m | 9.5 m | 10.2 m | 11.1 m |
| USD | Y, 2017 |
|---|---|
Revenue/Employee | 588.2 |
